The American College of Medical Genetics and Genomics (ACMG) has published a new clinical practice resource, Management of Individuals with Heterozygous Germline Pathogenic Variants in RAD51C, RAD51D, and BRIP1, published in Genetics in Medicine. The resource provides evidence-based guidance for clinicians managing patients with these moderate-penetrance variants, which are associated with elevated risks for ovarian and breast cancers. It offers recommendations for risk-reducing surgery, breast surveillance, and patient counseling, while emphasizing the importance of personalized care informed by family history and genetic context. Lead author Dr. Joanne Ngeow and senior author Dr. Helen Hanson highlight the resource’s role in translating rapidly advancing genetic research into clinical practice and ensuring patients receive actionable, up-to-date care.

Cambridge, MA, Nov 10th ,2025 — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly (“Lilly”) that the two parties will combine Insilico’s state-of-the-art Pharma.AI platforms with Lilly’s development and disease expertise to jointly discover and advance innovative therapies.

Cannabis may be a pain-management substitute for people experiencing chronic or acute pain from conditions like cancer, according to new research from the University of Georgia.

TORONTO (November 10, 2025)—Millions of very young children currently excluded from treatment with the drug ivermectin could be safely included in ongoing campaigns against challenging and often neglected tropical diseases such as intestinal worms, scabies and river blindness, according to results from a clinical trial presented today at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this in using insurance claims data. They found that semaglutide and tirzepatide – marketed as Ozempic and Mounjaro – reduced the risk of serious cardiovascular events by up to 18 percent.